| HOME >> BIOLOGY >> TECHNOLOGY |
Land use rights, net 5,333 5,160
Other non-current assets 4,309 2,183
Total non-current assets 260,871 81,898
Total assets 408,292 343,775
Liabilities and shareholders' equity:
Current liabilities:
Short-term bank borrowings, current 7,830 --
Accounts payable 14,017 7,216
Accrued expenses 13,262 12,279
Deferred revenue 13,215 19,706
Advanced subsidies 2,074 1,077
Other taxes payable 4,039 4,060
Other current liabilities 3,432 1,233
Total current liabilities 57,869 45,571
Non-current liabilities:
Long-term debt, excluding current portion 10,588 4,108
Advanced subsidies 2,339 1,529
Convertible notes 35,864 40,988
Deferred tax liabilities (Note 1) 3,897 181
Other non-current liabilities 2,980 --
Total non-current liabilities 55,668 46,806
Total liabilities 113,537 92,377
Shareholders' equity:
Ordinary shares (Note 2), ($0.02 par
value, 5,002,550,000 authorized
492,226,776 and 499,600,302 issued
and outstanding as of December 31,
2007 and March 31, 2008, respectively) 9,992 9,845
Additional paid-in capital 314,146 291,020
Accumu
'/>"/>
| SOURCE WuXi PharmaTech Copyright©2008 PR Newswire. All rights reserved |